Literature DB >> 27292318

CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia.

A Kariminejad1, L Schöls2, R Schüle3, S H Tonekaboni4, A Abolhassani5, M Fadaee5, R O Rosti6, J G Gleeson6.   

Abstract

Hereditary spastic paraplegia (HSP) is a heterogeneous condition characterized by progressive spasticity and weakness in the lower limbs. It is divided into two major groups, complicated and uncomplicated, based on the presence of additional features such as intellectual disability, ataxia, seizures, peripheral neuropathy and visual problems. SPG56 is an autosomal recessive form of HSP with complicated and uncomplicated manifestations, complicated being more common. CYP2U1 gene mutations have been identified as responsible for SPG56. Intellectual disability, dystonia, subclinical sensory motor neuropathy, pigmentary degenerative maculopathy, thin corpus callosum and periventricular white-matter hyperintensities were additional features noted in previous cases of SPG56. Here we identified two novel mutations in CYP2U1 in two unrelated patients by whole exome sequencing. Both patients had complicated HSP with activity-induced dystonia, suggesting dystonia as an additional finding in SPG56. Two out of 14 previously reported patients had dystonia, and the addition of our patients suggests dystonia in a quarter of SPG56 patients. Developmental regression has not been reported in SPG56 patients so far but both of our patients developed motor regression in infancy.
Copyright © 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CYP2U1; Complicated; Dystonia; Hereditary spastic paraplegia; Regression; SPG56

Mesh:

Substances:

Year:  2016        PMID: 27292318      PMCID: PMC5011458          DOI: 10.1016/j.ejpn.2016.05.013

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  18 in total

1.  Pigmentary degenerative maculopathy as prominent phenotype in an Italian SPG56/CYP2U1 family.

Authors:  Luca Leonardi; Lucia Ziccardi; Christian Marcotulli; Anna Rubegni; Antonino Longobardi; Mariano Serrao; Eugenia Storti; Francesco Pierelli; Alessandra Tessa; Vincenzo Parisi; Filippo M Santorelli; Casali Carlo
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

2.  Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis.

Authors:  Andrea Citterio; Alessia Arnoldi; Elena Panzeri; Maria Grazia D'Angelo; Massimiliano Filosto; Robertino Dilena; Filippo Arrigoni; Marianna Castelli; Cristina Maghini; Chiara Germiniasi; Francesca Menni; Andrea Martinuzzi; Nereo Bresolin; Maria Teresa Bassi
Journal:  J Neurol       Date:  2013-12-13       Impact factor: 4.849

3.  Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients.

Authors:  Rebecca Schüle; Sarah Wiethoff; Peter Martus; Kathrin N Karle; Susanne Otto; Stephan Klebe; Sven Klimpe; Constanze Gallenmüller; Delia Kurzwelly; Dorothea Henkel; Florian Rimmele; Henning Stolze; Zacharias Kohl; Jan Kassubek; Thomas Klockgether; Stefan Vielhaber; Christoph Kamm; Thomas Klopstock; Peter Bauer; Stephan Züchner; Inga Liepelt-Scarfone; Ludger Schöls
Journal:  Ann Neurol       Date:  2016-03-11       Impact factor: 10.422

4.  Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).

Authors:  Michael C Kruer; Coro Paisán-Ruiz; Nathalie Boddaert; Moon Y Yoon; Hiroko Hama; Allison Gregory; Alessandro Malandrini; Randall L Woltjer; Arnold Munnich; Stephanie Gobin; Brenda J Polster; Silvia Palmeri; Simon Edvardson; John Hardy; Henry Houlden; Susan J Hayflick
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

Review 5.  Cellular pathways of hereditary spastic paraplegia.

Authors:  Craig Blackstone
Journal:  Annu Rev Neurosci       Date:  2012-04-20       Impact factor: 12.449

Review 6.  Hereditary spastic paraplegias: an update.

Authors:  Christel Depienne; Giovanni Stevanin; Alexis Brice; Alexandra Durr
Journal:  Curr Opin Neurol       Date:  2007-12       Impact factor: 5.710

Review 7.  Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms.

Authors:  John K Fink
Journal:  Acta Neuropathol       Date:  2013-07-30       Impact factor: 17.088

8.  Tunisian hereditary spastic paraplegias: clinical variability supported by genetic heterogeneity.

Authors:  A Boukhris; G Stevanin; I Feki; P Denora; N Elleuch; M I Miladi; C Goizet; J Truchetto; S Belal; A Brice; C Mhiri
Journal:  Clin Genet       Date:  2009-05-05       Impact factor: 4.438

9.  Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia.

Authors:  Christelle Tesson; Magdalena Nawara; Mustafa A M Salih; Rodrigue Rossignol; Maha S Zaki; Mohammed Al Balwi; Rebecca Schule; Cyril Mignot; Emilie Obre; Ahmed Bouhouche; Filippo M Santorelli; Christelle M Durand; Andrés Caballero Oteyza; Khalid H El-Hachimi; Abdulmajeed Al Drees; Naima Bouslam; Foudil Lamari; Salah A Elmalik; Mohammad M Kabiraj; Mohammed Z Seidahmed; Typhaine Esteves; Marion Gaussen; Marie-Lorraine Monin; Gabor Gyapay; Doris Lechner; Michael Gonzalez; Christel Depienne; Fanny Mochel; Julie Lavie; Ludger Schols; Didier Lacombe; Mohamed Yahyaoui; Ibrahim Al Abdulkareem; Stephan Zuchner; Atsushi Yamashita; Ali Benomar; Cyril Goizet; Alexandra Durr; Joseph G Gleeson; Frederic Darios; Alexis Brice; Giovanni Stevanin
Journal:  Am J Hum Genet       Date:  2012-11-21       Impact factor: 11.025

10.  Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia.

Authors:  Simon Edvardson; Hiroko Hama; Avraham Shaag; John Moshe Gomori; Itai Berger; Dov Soffer; Stanley H Korman; Ilana Taustein; Ann Saada; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2008-11       Impact factor: 11.025

View more
  5 in total

Review 1.  Cytochrome P450 2U1, a very peculiar member of the human P450s family.

Authors:  L Dhers; L Ducassou; J-L Boucher; D Mansuy
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

2.  Long-term follow-up in spastic paraplegia due to SPG56/CYP2U1: age-dependency rather than genetic variability?

Authors:  Alessandro Iodice; Celeste Panteghini; Carlotta Spagnoli; Grazia Gabriella Salerno; Daniele Frattini; Carmela Russo; Barbara Garavaglia; Carlo Fusco
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

3.  Encephalopathies with intracranial calcification in children: clinical and genetic characterization.

Authors:  Davide Tonduti; Celeste Panteghini; Anna Pichiecchio; Alice Decio; Miryam Carecchio; Chiara Reale; Isabella Moroni; Nardo Nardocci; Jaume Campistol; Angela Garcia-Cazorla; Belen Perez Duenas; Luisa Chiapparini; Barbara Garavaglia; Simona Orcesi
Journal:  Orphanet J Rare Dis       Date:  2018-08-16       Impact factor: 4.123

Review 4.  Lipid metabolic pathways converge in motor neuron degenerative diseases.

Authors:  Olivia J Rickman; Emma L Baple; Andrew H Crosby
Journal:  Brain       Date:  2020-04-01       Impact factor: 13.501

5.  Implication of folate deficiency in CYP2U1 loss of function.

Authors:  Anne Legrand; Livia Parodi; Claire Pujol; Priscilla Thomas; Fanny Mochel; Dario Saracino; Giulia Coarelli; Marijana Croon; Milica Popovic; Manon Valet; Nicolas Villain; Shahira Elshafie; Mahmoud Issa; Stephane Zuily; Mathilde Renaud; Cécilia Marelli-Tosi; Marine Legendre; Aurélien Trimouille; Isabelle Kemlin; Sophie Mathieu; Joseph G Gleeson; Foudil Lamari; Daniele Galatolo; Rana Alkouri; Chantal Tse; Diana Rodriguez; Claire Ewenczyk; Florence Fellmann; Thierry Kuntzer; Emilie Blond; Khalid H El Hachimi; Frédéric Darios; Alexandre Seyer; Anastasia D Gazi; Patrick Giavalisco; Silvina Perin; Jean-Luc Boucher; Laurent Le Corre; Filippo M Santorelli; Cyril Goizet; Maha S Zaki; Serge Picaud; Arnaud Mourier; Sophie Marie Steculorum; Cyril Mignot; Alexandra Durr; Aleksandra Trifunovic; Giovanni Stevanin
Journal:  J Exp Med       Date:  2021-09-21       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.